Zymeworks announced updated financial guidance for FY26, including total sales and adjusted EBITDA, following its acquisition of Theravance Biopharma. The acquisition adds YUPELRI to its portfolio, providing a recurring cash flow stream and significant Irish tax attributes, which are expected to drive long-term value.
Zymeworks has completed its acquisition of Theravance Biopharma, a significant strategic move that immediately impacts its financial outlook. The company is now guiding for substantial FY26 total sales and adjusted EBITDA, largely driven by the addition of YUPELRI, which provides a durable, recurring cash flow. This acquisition is a major catalyst for Zymeworks, as it not only diversifies its revenue streams but also brings valuable Irish tax attributes and R&D assets. Short-term, the market will likely react positively to the clear financial guidance and the strategic rationale. Long-term, the success hinges on Zymeworks' ability to integrate the new assets, leverage the tax attributes, and continue growing YUPELRI sales, especially through the hospital channel. The potential $100 million TRELEGY ELLIPTA milestone payment in Q1 2027 also presents a significant opportunity to offset acquisition costs.